# EDGAR Filing Document

**Accession Number:** 0001889109
**File Stem:** 0001104659-23-022321
**Filing Date:** 2023-2
**Character Count:** 10492
**Document Hash:** 1146545cb38907dc2d662a8df175a73e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-022321.hdr.sgml**: 20230215

**ACCESSION NUMBER**: 0001104659-23-022321

**CONFORMED SUBMISSION TYPE**: SC 13G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230215

**DATE AS OF CHANGE**: 20230215

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BELITE BIO, INC
- **CENTRAL INDEX KEY:** 0001889109
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93970
- **FILM NUMBER:** 23634804

**BUSINESS ADDRESS:**
- **STREET 1:** 5820 OBERLIN DRIVE, SUITE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-246-6240

**MAIL ADDRESS:**
- **STREET 1:** 5820 OBERLIN DRIVE, SUITE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LIn Yu-Hsin
- **CENTRAL INDEX KEY:** 0001965964

**FILING VALUES:**
- **FORM TYPE:** SC 13G

**MAIL ADDRESS:**
- **STREET 1:** 5820 OBERLIN DRIVE, SUITE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934\***

---

| |
|:---|
| **Belite Bio, Inc** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Name of Issuer) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Ordinary shares, par value US$0.0001 per share** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Title of Class of Securities) |
| **07782B 104\*\*** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(CUSIP Number) |
| **December 31, 2022** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Date of Event which Requires Filing of this Statement) |

---

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

◻ Rule 13d-1(b) <br> ◻ Rule 13d-1(c) <br> ⌧ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

\*\* There is no CUSIP number assigned to the ordinary shares of the Issuer ("Ordinary Shares"). CUSIP number 07782B 104 has been assigned to the American Depositary Shares ("ADSs") of the Issuer, which are quoted on NASDAQ Capital Market under the symbol "BLTE". Each ADS represents one Ordinary Share.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

---

| | | |
|:---|:---|:---|
| **CUSIP No. 07782B 104** | **SCHEDULE 13G** | **Page 2 of 4 Pages** |

---

---

| | | | |
|:---|:---|:---|:---|
| 1 | &nbsp;&nbsp;NAMES OF REPORTING PERSONS<br>Yu-Hsin Lin | &nbsp;&nbsp;NAMES OF REPORTING PERSONS<br>Yu-Hsin Lin | &nbsp;&nbsp;NAMES OF REPORTING PERSONS<br>Yu-Hsin Lin |
| 2 | &nbsp;&nbsp;CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP<br> (a) ◻<br> (b) ◻ | &nbsp;&nbsp;CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP<br> (a) ◻<br> (b) ◻ | &nbsp;&nbsp;CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP<br> (a) ◻<br> (b) ◻ |
| 3 | &nbsp;&nbsp;SEC USE ONLY | &nbsp;&nbsp;SEC USE ONLY | &nbsp;&nbsp;SEC USE ONLY |
| 4 | &nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>Australia | &nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>Australia | &nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>Australia |
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY<br>EACH<br>REPORTING<br>PERSON WITH | NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY<br>EACH<br>REPORTING<br>PERSON WITH | 5 | &nbsp;&nbsp;SOLE VOTING POWER<br>2,485,308<br>|
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY<br>EACH<br>REPORTING<br>PERSON WITH | NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY<br>EACH<br>REPORTING<br>PERSON WITH | 6 | &nbsp;&nbsp;SHARED VOTING POWER<br>|
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY<br>EACH<br>REPORTING<br>PERSON WITH | NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY<br>EACH<br>REPORTING<br>PERSON WITH | 7 | &nbsp;&nbsp;SOLE DISPOSITIVE POWER<br>2,485,308<br>|
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY<br>EACH<br>REPORTING<br>PERSON WITH | NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY<br>EACH<br>REPORTING<br>PERSON WITH | 8 | &nbsp;&nbsp;SHARED DISPOSITIVE POWER<br>0<br>|
| 9 | &nbsp;&nbsp;AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>2,485,308<sup>(1)</sup> | &nbsp;&nbsp;AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>2,485,308<sup>(1)</sup> | &nbsp;&nbsp;AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>2,485,308<sup>(1)</sup> |
| 10 | &nbsp;&nbsp;CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ◻<br>◻ | &nbsp;&nbsp;CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ◻<br>◻ | &nbsp;&nbsp;CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ◻<br>◻ |
| 11 | &nbsp;&nbsp;PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>9.97%<sup>(2)</sup> | &nbsp;&nbsp;PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>9.97%<sup>(2)</sup> | &nbsp;&nbsp;PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>9.97%<sup>(2)</sup> |
| 12 | &nbsp;&nbsp;TYPE OF REPORTING PERSON<br>IN | &nbsp;&nbsp;TYPE OF REPORTING PERSON<br>IN | &nbsp;&nbsp;TYPE OF REPORTING PERSON<br>IN |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Include (i) 731,728 Ordinary Shares directly
 held by Yu-Hsin Lin; (ii) 22,777 Ordinary Shares underlying share options granted to Yu-Hsin
 Lin that are vested or will be vested within 60 days of December 31, 2022; and (iii) 1,730,803
 Ordinary Shares indirectly held by Yu-Hsin Lin through Lin Bioscience International Ltd.,
 which is our principal shareholder and the wholly-owned subsidiary of our controlling shareholder
 Lin BioScience, Inc.(stock code: 6696.TW).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The percentage is calculated based upon
 an aggregate of (i) 24,898,908 Ordinary Shares outstanding as of December 31, 2022 as provided
 by the Issuer; and (ii) 22,777 Ordinary Shares underlying share options granted to Yu-Hsin
 Lin that are vested or will be vested within 60 days of December 31, 2022.

---

| | | |
|:---|:---|:---|
| **CUSIP No. 07782B 104** | **SCHEDULE 13G** | **Page 3 of 4 Pages** |

---

---

| | |
|:---|:---|
| **Item 1(a)** | <u>Name of Issuer</u>: |

---

Belite Bio, Inc (the "Issuer")

---

| | |
|:---|:---|
| **Item 1(b)** | <u>Address of Issuer's Principal Executive Offices</u>: |

---

5820 Oberlin Drive, Suite 101,

San Diego, CA 92121

United States of America

---

| | |
|:---|:---|
| **Item 2(a)** | <u>Name of Persons Filin</u>g: |

---

This Schedule 13G is filed on behalf of Yu-Hsin Lin ("Reporting Person")

---

| | |
|:---|:---|
| **Item 2(b)** | <u>Address of Principal Business Office or, If None, Residence</u> |

---

The business address of the Reporting Person is 36F., No. 68, Sec. 5, Zhongxiao E. Rd., Xinyi Dist., Taipei City 110, Taiwan

---

| | |
|:---|:---|
| **Item 2(c)** | <u>Citizenshi</u>p |

---

Yu-Hsin Lin is a citizen of Australia

---

| | |
|:---|:---|
| **Item 2(d)** | <u>Title of Class of Securities</u>: |

---

Ordinary Shares, par value $0.0001 per share

---

| | |
|:---|:---|
| **Item 2(e)** | <u>CUSIP Number</u>: |

---

07782B 104

**Item 3.** <u>Statement Filed Pursuant to Rule 13d-1(b) or 13d-2(b) or (c):</u>

Not applicable.

**Item 4.** <u>Ownershi</u>p

The information for the Reporting Person contained in rows 5-11 of the cover page and Item 2(a) is incorporated herein by reference.

**Item 5.** <u>Ownership of Five Percent or Less of a Class</u>

Not applicable.

**Item 6.** <u>Ownership of More Than Five Percent on Behalf of Another Person</u>

Not applicable.

**Item 7.** <u>Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person</u>

Not applicable.

**Item 8.** <u>Identification and Classification of Members of the Grou</u>p

Not applicable.

**Item 9.** <u>Notice of Dissolution of Group</u>

Not applicable.

**Item 10.** <u>Certifications</u>

Not applicable.

---

| | | |
|:---|:---|:---|
| **CUSIP No. 07782B 104** | **SCHEDULE 13G** | **Page 4 of 4 Pages** |

---

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

---

| | | |
|:---|:---|:---|
| Dated: February 15, 2023 |  |  |
|  | Yu-Hsin Lin | Yu-Hsin Lin |
|  | By: | /s/Yu-Hsin Lin |
|  | Name: | Yu-Hsin Lin |
|  | Title: | Chief Executive Officer and Chairman |

---